This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



netupitant/palonosetron (Akynzeo®)


Reference No. 1484

Publication date:
27/07/2016


Last review date:
01/08/2019

Appraisal information

netupitant/palonosetron (Akynzeo®) 300 mg/0.5 mg capsule


Company: Chugai Pharma UK Ltd
BNF category: Central nervous system
NMG meeting date: 08/06/2016
AWMSG meeting date: 13/07/2016
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 2016
Ratification by Welsh Government: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Netupitant/palonosetron (Akynzeo®) is recommended as an option for restricted use within NHS Wales for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin­based cancer chemotherapy in adults. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Netupitant/palonosetron (Akynzeo®) is not recommended for use within NHS Wales for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download